Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Haematologica|May 21, 2026
[18F]Fluorodeoxyglucose-PET/MRI-based response assessment following BCMA-directed CAR-T-cell therapy with ciltacabtagene autoleucel in relapsed/refractory multiple myelomaRaphael Teipel, Karolin Trautmann-Grill, Luisa Kleditsch, et al.
Cancers|October 14, 2022
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression AnalysisAnke Schilhabel, Peter Jonas Walter, Paula Cramer, et al.
Epilepsia|August 22, 2021
Wearable devices for seizure detection: Practical experiences and recommendations from the Wearables for Epilepsy And Research (WEAR) International Study GroupElisa Bruno, Sebastian Böttcher, Pedro F Viana, et al.
Scientific Reports|December 10, 2022
Data quality evaluation in wearable monitoringSebastian Böttcher, Solveig Vieluf, Elisa Bruno, et al.
European Journal of Haematology|November 19, 2016
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trialOthman Al-Sawaf, Kirsten Fischer, Carmen D Herling, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 20, 2010
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignanciesNicolaus Kröger, Ulrike Bacher, Peter Bader, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2024
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple MyelomaJanine Kirchberg, Luise Fischer, Patrick Born, et al.
Blood|December 20, 2017
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLLNatalie Dimier, Paul Delmar, Carol Ward, et al.
British Journal of Haematology|February 19, 2021
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN studyStephan Stilgenbauer, Francesc Bosch, Osman Ilhan, et al.
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Pageof 12